Related Experiment Video

Updated: May 11, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Opportunities and challenges for successful use of bevacizumab in pediatrics

Amy Barone1, Joshua B Rubin

  • 1Division of Pediatric Hematology and Oncology, Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine St. Louis, MO, USA.

Frontiers in Oncology
|May 4, 2013
PubMed

Insights

Bevacizumab (Avastin) shows promise in pediatric cancers, with notable success in low-grade tumors affecting vision and hearing. Further research into resistance mechanisms is crucial for future pediatric clinical trials.

Area of Science:

  • Oncology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Bevacizumab (Avastin) is an established cancer treatment in adults across various histologies.
  • Its application is expanding into pediatric oncology and non-oncologic indications.
  • Pediatric responses to bevacizumab may differ from adult responses.

Purpose of the Study:

  • To review the oncologic and non-oncologic uses of bevacizumab in pediatric patients.
  • To evaluate the efficacy and safety of bevacizumab in pediatric malignancies.
  • To identify mechanisms of bevacizumab resistance in pediatric cancers.

Main Methods:

  • Review of existing literature and clinical trial data on bevacizumab in pediatric populations.
  • Analysis of treatment outcomes, including tumor response and functional recovery.
  • Investigation into molecular mechanisms underlying bevacizumab resistance.

Main Results:

  • Bevacizumab demonstrates activity in pediatric cancers, though responses may be more limited than in adults.
  • Significant tumor response and functional recovery (vision, hearing) observed in low-grade pediatric tumors.
  • Established non-oncologic uses for bevacizumab in pediatric conditions.
  • Identified several mechanisms contributing to bevacizumab resistance.

Conclusions:

  • Bevacizumab offers therapeutic potential in pediatric oncology and other conditions.
  • Its use in low-grade tumors threatening vision and hearing is particularly promising.
  • Understanding resistance mechanisms is key to optimizing future pediatric bevacizumab trials.
Keywords:
VEGFanti-angiogenicbevacizumabglioblastomapediatric

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...